Publication Name	World Journal of Cardiology
Manuscript ID	127591
DOI	10.4330/wjc.127591
Country	China

Category	Medicine, Research & Experimental
Manuscript Type	Minireviews
Article Title	Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy
Manuscript Source	Invited Manuscript
All Author List	Yi-Ze Qi, Zhi-Yuan Wang and Xiang-Dong Li
Funding Agency and Grant Number
Corresponding Author	Xiang-Dong Li, Department of Cardiology, China-Japan Union Hospital of Jilin University, No.126 Xiantai Avenue, Changchun 130033, Jilin Province, China. lxd870112@jlu.edu.cn
Key Words	Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Cardio-hepatic axis; Heart failure with preserved ejection fraction; Glucagon-like peptide-1 receptor agonist; Sodium-glucose cotransporter 2 inhibitor; Fibrosis-4 index
Core Tip	This review reframes metabolic dysfunction associated steatotic liver disease as a cardiovascular and metabolic risk signal, not merely a liver disease. The core framework is as follows: Use the fibrosis-4 index for first-layer fibrosis risk triage; identify three main clinical phenotypes, including obesity/metabolic burden, atherosclerotic cardiovascular disease, and heart failure/chronic kidney disease; and then prioritize incretin-based therapies or sodium-glucose cotransporter 2 inhibitors. Fibrosis stage serves as an independent risk modifier to guide hepatology collaboration and discussion of combination therapy. Combination therapy remains a second-layer strategy with limited evidence and requires individualized discussion.
Citation	Qi YZ, Wang ZY, Li XD. Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy. World J Cardiol 2026; In press DOI: https://doi.org/10.4330/wjc.127591
PDF	127591-in-press.pdf

Received	2026-09-02 08:35
Peer-Review Started	2026-09-02 08:36
First Decision by Editorial Office Director
Return for Revision	2026-09-23 08:11
Revised	2026-10-05 14:22
Publication Fee Transferred
Second Decision by Editor	2026-11-05 02:07
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-11-05 09:13
Articles in Press	2026-11-05 09:13
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1949-8462 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com